METiS Technologies，中国“四大AI制药独角兽”之一，近日宣布完成4亿元人民币（约合5500万美元）的D轮融资。本轮融资由北京医药健康产业投资基金和亦庄国投共同领投，将用于加速其AI驱动的纳米递送系统和下一代细胞与基因疗法（CGT）的研发与全球扩张。METiS成立于2020年，专注于利用AI技术创新纳米材料以实现精准药物递送，已获得超20亿元人民币融资。公司拥有AiLNP、AiRNA和AiTEM三大核心AI平台，并在多器官、多组织药物递送方面取得显著进展。此次融资将助力其平台自动化升级、自有药物管线推进和人才引进。同时，METiS推出了“Open CGT”平台，旨在降低CGT研发门槛，加速临床转化，并已与锐正基因达成首个合作。公司CEO赖才达表示，AI驱动的药物发现是长期过程，科学本身是最大挑战，行业发展需加强全产业链协作。

🚀 **AI赋能纳米递送与CGT研发**：METiS Technologies专注于利用人工智能技术创新纳米材料，以实现精准药物递送，并致力于下一代细胞与基因疗法（CGT）的研发。公司已开发出AiLNP（核酸递送）、AiRNA（mRNA序列设计）和AiTEM（小分子制剂设计）三大核心AI平台，并在肝脏、肺部、肌肉和免疫细胞的脂质纳米颗粒（LNP）递送方面取得了重要突破，有效解决了多器官、多组织药物递送的关键技术难题。

💰 **巨额融资加速发展**：METiS Technologies此次完成了4亿元人民币（约5500万美元）的D轮融资，由北京医药健康产业投资基金和亦庄国投联合领投。这笔资金将用于支持公司平台自动化升级、自有药物管线的推进、全球化扩张以及高端人才的引进。公司自2020年成立以来，已累计获得超过20亿元人民币的融资，显示出其在资本市场的强大吸引力。

💡 **“Open CGT”平台推动行业进步**：为降低细胞与基因疗法的研发门槛、成本并加速临床转化，METiS Technologies推出了其“Open CGT”平台。该平台旨在赋能新兴技术和早期管线，提供将创新成果从实验室推向临床所需的递送解决方案。首个合作项目是与锐正基因合作，利用mRNA-LNP技术开发靶向肝脏的CRISPR基因编辑疗法。

📈 **中国生物医药行业新机遇**：中国生物医药行业正迎来发展新动能，资本市场对创新疗法，特别是高风险高回报的CGT领域信心回升。METiS Technologies的CEO赖才达指出，这种积极趋势为公司提供了更有利的外部环境。同时，公司位于北京大兴区，该区域正积极打造“中国药谷”，为生物医药创新提供战略支持。

🔬 **长期主义与科学挑战**：METiS Technologies的CEO赖才达强调，AI驱动的药物发现是一个长期的系统工程，公司最大的竞争对手是科学本身，而非其他企业。他认为，当前CGT行业仍处于早期阶段，跨越价值链的合作对于推动突破至关重要。公司的一款领先的AI驱动制剂候选药物已完成III期临床试验，正迈向新药申请（NDA）提交阶段，标志着公司发展的重要里程碑。

 Lai Caida, METiS Technologies Co-founder and CEO

TMTPOST — METiS Technologies, one of China’s so-called “Four AI Pharma Unicorns,” has raised 400 million yuan ($55 million) in a Series D financing round, bolstering its ambitions in AI-powered nano-delivery systems and next-generation cell and gene therapies (CGT).

The round was jointly led by the Beijing Pharmaceutical Health Industry Investment Fund and Daxing District Industrial Investment Fund, METiS announced on Sunday. The fresh capital will support the company’s platform automation upgrades, advancement of proprietary drug pipelines, global expansion initiatives, and top-tier talent recruitment.

Founded in 2020, METiS specializes in AI-driven nanomaterial innovation for precision drug delivery. To date, the company has secured over 2 billion yuan (approximately $300 million) in funding from prominent investors including CICC Capital, Sequoia China, China Life Equity, and PICC Capital.

“This round is a strong endorsement of METiS’s strategic vision and long-term approach,” said Dr. Lai Caida, Co-founder and CEO of METiS Technologies. “We are committed to leveraging AI innovation to solve the complex challenges of nano-delivery and contribute to the high-quality development of China’s CGT industry.”

METiS has developed three core AI platforms—AiLNP for nucleic acid delivery, AiRNA for mRNA sequence design, and AiTEM for small molecule formulation design. The company has achieved notable breakthroughs in lipid nanoparticle (LNP) delivery targeting the liver, lungs, muscles, and immune cells, addressing key hurdles in multi-organ, multi-tissue drug delivery.

Coinciding with the new funding, METiS launched its “Open CGT” platform—an industry-facing initiative to reduce development barriers, lower costs, and accelerate the clinical translation of cell and gene therapies. Its first collaboration under the platform is with Ruizheng Gene, developing a liver-targeted CRISPR gene editing therapy using mRNA-LNP technology.

“CGT will undoubtedly become a pillar of China’s biopharmaceutical landscape,” Lai said. “Through Open CGT, METiS aims to empower emerging technologies and early-stage pipelines, providing the delivery solutions needed to bring these innovations from lab to clinic.”

China’s biotech sector is witnessing a surge in momentum, with confidence returning to capital markets and primary-stage investments. Lai highlighted that this positive trend is creating a more favorable environment for companies like METiS, especially in high-risk, high-reward segments such as CGT.

Daxing District, where METiS is based, has positioned itself as a key innovation hub under the “China Medicine Valley” initiative. Li Ming, Chairman of Daxing District Investment Group, a lead investor in this round, stated: “METiS’s Open CGT platform will accelerate the commercialization of original innovations and attract global talent, technology, and capital to Daxing.”

On the product front, METiS’s lead AI-driven formulation drug candidate has completed Phase III clinical trials and is moving towards NDA submission, marking a significant milestone for the company.

Lai emphasized that AI-driven drug discovery remains a long-term endeavor. “Our biggest competitor isn’t other companies—it’s science itself,” he said. “This industry is in its early stages, and collaboration across the value chain will be essential to drive breakthroughs.”

Alongside Deep Intelligent Pharma, XtalPi, and Insilico Medicine, METiS Technologies is widely recognized as one of China’s “Four Rising Stars of AI Pharma.”

更多精彩内容，关注钛媒体微信号（ID：taimeiti），或者下载钛媒体App